New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free

Triptorelin

Also known as: Decapeptyl, Trelstar, GnRH Superagonist, D-Trp6-LHRH

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.

Half-Life

Depot forms: weeks to months; aqueous: 6-8 hours

Route

SubQ, IM

Category

Sexual Health & Libido

Studies

50 references

Key Benefits

  • Rapid HPG axis restart after steroid use
  • Single-injection PCT protocol possible
  • Massively elevates LH and FSH via flare effect
  • Restores endogenous testosterone faster than traditional PCT
  • FDA-approved for established medical uses

Mechanism of Action

As a GnRH superagonist, a single large dose causes massive LH and FSH release (flare effect), which can jumpstart endogenous testosterone production. This distinguishes it from pulsatile GnRH (gonadorelin) — one injection provides a powerful, sustained HPG stimulation. With repeated dosing, it paradoxically causes HPG suppression (used in prostate cancer).

Dosing Protocols

PCT Single-Shot Protocol

Dose
100 mcg
Frequency
Single injection
Timing
1-2 weeks after last steroid dose
Cycle
One-time use for PCT

Causes acute LH/FSH surge to jumpstart HPG axis; follow with SERMs if needed

Medical Depot Formulation

Dose
3.75 mg depot
Frequency
Once monthly
Timing
IM or SC depot injection
Cycle
Ongoing for prostate cancer

Medical use only; causes HPG suppression not stimulation at this dosing regimen

Calculate your draw volume

Enter your vial size and BAC water to get exact injection volumes

Calculate dose →

Side Effects

  • Initial testosterone flare (intended)
  • Injection site reactions
  • Hot flashes (with chronic use)
  • Decreased libido (chronic dosing)

Storage

Lyophilized: refrigerate at 2-8°C. Reconstituted: use immediately.

  1. 1.
    Effect of emulsion-based nanosystems on the encapsulation behavior of triptorelin using molecular dynamics simulation

    Nejati F, Ahmadian N, Yahyaei M, Mehrnejad F · Journal of computer-aided molecular design · 2026PubMed Verified

  2. 2.
    Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study

    Tran B, Yeh N, Gayle A, Holmes E, Hu J, Damineni S et al. · ESMO real world data and digital oncology · 2025ReviewPubMed Verified

  3. 3.
  4. 4.
    Efficacy and outcomes of 6-month triptorelin formulation in girls treated for central precocious puberty for 24 months and beyond

    Foreman A, Klein KO, Vargas Trujillo M · Journal of pediatric endocrinology & metabolism : JPEM · 2026PubMed Verified

  5. 5.
    GnRH Administration Increases Synchronisation of Ovulation in Mares

    Cui B, Liu Y, Wu X, Li X · Reproduction in domestic animals = Zuchthygiene · 2026PubMed Verified

  6. 6.
    Benefits of Implant Use in the Cow/Calf and Backgrounding Sectors

    Sperber JL, Nuttelman B, MacDonald J · The Veterinary clinics of North America. Food animal practice · 2026ReviewPubMed Verified

  7. 7.
    Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis

    Sandhu K, Wells C, Newton MMH, Murphy DG, Lawrentschuk N, Perera ML · International urology and nephrology · 2026PubMed Verified

  8. 8.
    Design and synthesis of graphite/Ni/Cu/triptorelin peptide electrocatalyst for hydrogen production and storage

    Ferdowsi GS, Jafarian M, Ramezanpour S, Aghamirza Moghim Aliabadi H · Scientific reports · 2026PubMed Verified

  9. 9.
    Diagnostic accuracy of the triptorelin stimulation test for central precocious puberty in girls

    Chioma L, Bizzarri C, Longobardi M, Mainieri F, Porzio O, D'Agostini M et al. · Endocrine connections · 2025PubMed Verified

  10. 10.
    Feasibility and efficacy of random-start progestin-primed ovarian stimulation: a multicenter pilot randomized controlled trial in oocyte donation

    Mathieu d'Argent E, Guivarc'h-Leveque A, Catteau-Jonard S, Cedrin-Durnerin I, Peigné M, Jung C et al. · Reproductive biology and endocrinology : RB&E · 2025PubMed Verified

  11. 11.
    Deslorelin influences canine epididymal gene expression of the androgen receptor and prostaglandin metabolism

    Greiner H, Packeiser EM, Körber H, Stempel S, Freise F, Goericke-Pesch S · Animal reproduction science · 2026PubMed Verified

  12. 12.
  13. 13.
  14. 14.
    Triptorelin: The Need for Legal Protection Aimed at the Full Political and Social Integration of Gender Variant youth. A Comparison of Different Global realities

    Lacasella G, Volonnino G, Salducci M, Ottavian M, Spadazzi F, Karaboue MAA et al. · La Clinica terapeutica · 2025ReviewPubMed Verified

  15. 15.
    Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer

    Friedrich NA, Janes JL, Parrish J, De Hoedt AM, Josan K, Tatonetti NP et al. · JAMA network open · 2025PubMed Verified

  16. 16.
    A case of congenital long QT syndrome and medically induced menopause

    Wilkinson JF, Williams PL, Green JC, Modi S, Briggs PE · Post reproductive health · 2025Case ReportPubMed Verified

  17. 17.
    Is the triptorelin stimulation test comparable to the gonadorelin stimulation test in diagnosing central precocious puberty in boys?

    Seo JH, Yoo MJ, Lee K, Choi J, Choe Y, Yang S · Annals of pediatric endocrinology & metabolism · 2025PubMed Verified

  18. 18.
    Efficacy of Huayu Xiaozheng decoction combined with triptorelin and mifepristone in the treatment of uterine fibroids and its effect on uterine artery hemodynamics

    Zhou Y, Liu X, Yang X, Yu Y, Zhou Y, Zhou H · International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025PubMed Verified

  19. 19.
    Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study

    Lebret T, Crehange G, Pello-Leprince-Ringuet N, Perrot V, Rigaud J · Therapeutic advances in urology · 2025PubMed Verified

  20. 20.
  21. 21.
    Serum proteomic profiling during the periovulatory period identifies preliminary candidate biomarkers of oocyte maturation in deslorelin-induced ovulation in dogs

    Udomthanaisit L, Roytrakul S, Kallayanathum W, Charoenlappanit S, Tharasanit T · PeerJ · 2025PubMed Verified

  22. 22.
    DEVELOPMENT AND VALIDATION OF DESLORELIN ACETATE ASSAY AND A PILOT STUDY ON THE PHARMACOKINETICS OF DESLORELIN ACETATE IMPLANTS AND FECAL HORMONE MONITORING IN THE DOMESTIC GOAT (CAPRA HIRCUS)

    Rooney TA, Lehner A, Zyskowski J, Thompson KA, Eustace R, Kozlowski CP et al. · Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians · 2025PubMed Verified

  23. 23.
  24. 24.
    Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam

    Kieu MTT, Le MH, Nguyen CP · Cost effectiveness and resource allocation : C/E · 2025PubMed Verified

  25. 25.
    Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis

    Xiong Y, Huang W, Wang C, Ma W, Jin S, Lin J et al. · BJOG : an international journal of obstetrics and gynaecology · 2026Meta-AnalysisPubMed Verified

  26. 26.
  27. 27.
    Role of triptorelin and single fixed-time artificial insemination on productive and reproductive performance of hyperprolific sows

    Falceto MV, Reyero D, Tejedor MT, Renaud P, Mateu A, Lafuente A et al. · Veterinary and animal science · 2025PubMed Verified

  28. 28.
    Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial

    Donno V, Neves AR, García-Martinez S, Rodriguez I, Polyzos NP · Fertility and sterility · 2025PubMed Verified

  29. 29.
  30. 30.
    Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate

    Thaneetrakool T, Aroonparkmongkol S, Chatdamrongsakool K, Numsriskulrat N, Supornsilchai V, Wacharasindhu S et al. · Annals of pediatric endocrinology & metabolism · 2025PubMed Verified

  31. 31.
  32. 32.
    Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data

    Jia W, Wang T · Scientific reports · 2025PubMed Verified

  33. 33.
    Triptorelin 0.1 mg as a Luteal Phase Support in Antagonist Intracytoplasmic Sperm Injection Cycles

    Zahran KM, Ahmed MMA, Farghaly TA, Elsayed AA, El-Nashar IM · Journal of obstetrics and gynaecology of India · 2025PubMed Verified

  34. 34.
    Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy

    Patel R, Weil E, Bugamelli S, Carroll E, Steinke K, Stockhausen E et al. · Breast cancer research : BCR · 2025PubMed Verified

  35. 35.
    Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

    Demogeot N, Sargos P, Salleron J, Guérif S, de Crevoisier R, Calais G et al. · European urology · 2025RCTPubMed Verified

  36. 36.
    Urinary follicle-stimulating hormone during triptorelin stimulation test can monitor the efficacy of triptorelin depot in girls with precocious or early puberty

    Zhou Y, Zeng B, Huang Y, Huang P, Li Y, Xu Z et al. · Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 2025PubMed Verified

  37. 37.
    Osteopontin expression in prepubertal and adult dog testes and the effect of slow-release deslorelin implants (Suprelorin® 4.7 mg)

    Liman N, Balogh O, Fidan B, Müller L, Gram A · Domestic animal endocrinology · 2025PubMed Verified

  38. 38.
    Apalutamide-associated rash combined with severe neutropenia and eosinophilia: a case report

    Shao Y, Liu Z, Zhang Y, Yang Z, Liu Y, Huang H et al. · AME case reports · 2025Case ReportPubMed Verified

  39. 39.
    AQbD-based development of a stability-indicating UHPLC-PDA-QDa method for triptorelin in parenteral formulations

    Afonso Urich JA, Marko V, Fedorko A, Jeremic D · Analytical methods : advancing methods and applications · 2025PubMed Verified

  40. 40.
    The GnRH Agonist Triptorelin Causes Reversible, Focal, and Partial Testicular Atrophy in Rats, Maintaining Sperm Production

    Marcos A, Rodríguez Del Cerro MC, Fernández RM, Pásaro E, Arias-Ramos N, López-Larrubia P et al. · International journal of molecular sciences · 2025PubMed Verified

  41. 41.
    Retrospective Analysis on the Impact of Triptorelin on Final Height of Girls with Precocious and Early Puberty: A Single-Center, Long-Term Study

    Sotiriou G, Serbis A, Galli-Tsinopoulou A, Christoforidis A · Children (Basel, Switzerland) · 2025PubMed Verified

  42. 42.
    Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study

    Chen Y, Lu W, Liao R, Zhang X, Chen W, Wang J et al. · PloS one · 2025PubMed Verified

  43. 43.
  44. 44.
  45. 45.
  46. 46.
    Effects of Different Gonadotropin-Releasing Hormone Agonists on IVF/ICSI-ET Outcomes in Long Protocol: A Retrospective Study

    Xu M, Li H, Zhao Y, Li H, Zhao C, Zhang X et al. · International journal of women's health · 2025PubMed Verified

  47. 47.
    Efficacy of first-year GnRHa therapy in girls with idiopathic central precocious puberty diagnosed after age 8: a retrospective study

    Ni MM, Yang ST, Sun JY, Wu WW, Li M, Gu W et al. · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2025PubMed Verified

  48. 48.
    Diagnosis Prostate Cancer via Molecular Computed Tomography Imaging based on Targeted Gold Nanoparticles

    Ghorbani F, Abbasi S, Rabani F, Khademi S, Montazerabadi A · Cell journal · 2025PubMed Verified

  49. 49.
    Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US

    Hafron J, Hong A, Ryan MJ, Romdhani H, Kinkead F, Flanders SC et al. · Future oncology (London, England) · 2025PubMed Verified

  50. 50.
    In vitro study of effect of gold nanoparticles conjugated with triptorelin peptide on the radiosensitivity of breast cancer cells (MCF-7)

    Tavakkoli E, Hashemi SM, Montazerabadi A, Khademi S, Ghorbani F, Mohammadzadeh S et al. · Discover oncology · 2025PubMed Verified

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.

Was this page helpful?

Launching soon

Build and track your protocol in Staqk

Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.

Free early access updates. No spam.